her2 tyrosine kinase inhibitor Latest Research Papers

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

Cancer Management and Research ◽

10.2147/cmar.s321428 ◽

2021 ◽

Vol Volume 13 ◽

pp. 7165-7174

Author(s):

Ying Sun ◽

Beibei Chen ◽

Jisheng Li ◽

Ling Peng ◽

Shuguang Li ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Real World ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Her2 Positive ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT

European Journal of Cancer ◽

10.1016/j.ejca.2020.11.045 ◽

2021 ◽

Vol 145 ◽

pp. 92-108

Author(s):

Hui Li ◽

Jinsong Wang ◽

Zongbi Yi ◽

Chunxiao Li ◽

Haijuan Wang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Breast Cancers ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment

Cell Cycle ◽

10.1080/15384101.2019.1624113 ◽

2019 ◽

Vol 18 (13) ◽

pp. 1513-1522 ◽

Cited By ~ 1

Author(s):

Jiayao Li ◽

Qian Xiao ◽

Yi Bao ◽

Wenyu Wang ◽

Jianyuan Goh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Mtor Signaling ◽

Inhibitor Treatment ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

European Journal of Cancer ◽

10.1016/j.ejca.2018.07.134 ◽

2018 ◽

Vol 103 ◽

pp. 17-23 ◽

Cited By ~ 2

Author(s):

H.-T. Arkenau ◽

A. Italiano ◽

G. Mak ◽

M. Toulmonde ◽

R.D. Baird ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Solid Tumours ◽

Extended Phase ◽

Phase Ib ◽

Orally Active ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin

Cardiovascular Toxicology ◽

10.1007/s12012-012-9183-x ◽

2012 ◽

Vol 13 (1) ◽

pp. 33-47 ◽

Cited By ~ 17

Author(s):

Brian B. Hasinoff ◽

Daywin Patel ◽

Xing Wu

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cardiac Myocyte ◽

Kinase Inhibitor ◽

Her2 Tyrosine Kinase Inhibitor ◽

Damaging Effects

Get full-text (via PubEx)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

Breast Cancer Research ◽

10.1186/bcr2799 ◽

2011 ◽

Vol 13 (1) ◽

Cited By ~ 1

Author(s):

Cristina Oliveras-Ferraros ◽

Sílvia Cufí ◽

Tamara Sauri-Nadal ◽

Sonia Del Barco ◽

Begoña Martin-Castillo ◽

...

Keyword(s):

Fatty Acid ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Fatty Acid Synthase ◽

Kinase Inhibitor ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

118 Responses of human pancreatic tumour cells to treatment with anti-EGFR mAb ICR62 and the irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor BIBW2992

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)71823-1 ◽

2010 ◽

Vol 8 (7) ◽

pp. 44

Author(s):

N. Ioannou ◽

A. Dalgleish ◽

A.M. Seddon ◽

D. Mackintosh ◽

U. Guertler ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Tumour Cells ◽

Pancreatic Tumour ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

Journal of Cellular Physiology ◽

10.1002/jcp.22333 ◽

2010 ◽

Vol 226 (1) ◽

pp. 52-57 ◽

Cited By ~ 19

Author(s):

Alejandro Vazquez-Martin ◽

Cristina Oliveras-Ferraros ◽

Silvia Cufí ◽

Sonia Del Barco ◽

Begoña Martin-Castillo ◽

...

Keyword(s):

Cell Growth ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cancer Cell ◽

Kinase Inhibitor ◽

Extracellular Domain ◽

Cancer Cell Growth ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1065 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1065-1065 ◽

Cited By ~ 6

Author(s):

M. H. Schuler ◽

M. M. Uttenreuther-Fischer ◽

M. J. Piccart-Gebhart ◽

N. Harbeck ◽

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Bibw 2992 ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.

10.1158/0008-5472.sabcs-09-5060 ◽

2009 ◽

Cited By ~ 18

Author(s):

T. Hickish ◽

D. Wheatley ◽

N. Lin ◽

L. Carey ◽

S. Houston ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Her2 Positive ◽

Bibw 2992 ◽

Her2 Tyrosine Kinase Inhibitor

Get full-text (via PubEx)

her2 tyrosine kinase inhibitor
Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT

HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

118 Responses of human pancreatic tumour cells to treatment with anti-EGFR mAb ICR62 and the irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor BIBW2992

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies.

Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.

Export Citation Format

her2 tyrosine kinase inhibitorRecently Published Documents

TOTAL DOCUMENTS

H-INDEX

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT

HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

118 Responses of human pancreatic tumour cells to treatment with anti-EGFR mAb ICR62 and the irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor BIBW2992

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies.

Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.

her2 tyrosine kinase inhibitor
Recently Published Documents